N/A N=667 LINK: Aftercare Monitoring Project
Alcohol Dependence · Drug Dependence
Primary: Rates of Substance Use — 91.1; 88.0 percentage of days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=225 Fronto-temporal tDCS Mproves Fluency & Empathy in ASD Kids
Autism · ASD
Primary: Verbal Fluency — 9.3; 10.5; 9.9; 8.3 units on a scale
Phase 3 N=677 Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
Diabetes Type 2
Primary: Change From Baseline in HbA1c to Week 52 — -0.59; -0.71 percent
N/A N=125 Telemedicine and Anger Management Groups With PTSD Veterans in the Hawaiian Islands
Posttraumatic Stress Disorder
Primary: State-Trait Anger Inventory (STAXI-2) Anger Expression Index — 56.7; 55.0 units on a scale
Phase 3 N=84 Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
Non-24-Hour Sleep-Wake Disorder
Primary: Proportion of Patients Entrained as Assessed by Urinary aMT6 — 20; 2.6 percentage of patients
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
Phase 4 N=18 Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
Behavior · Anxiety
Primary: Verbal and Nonverbal Behavior in Therapy Session: Effects of Drug — 34; 34.8; 45.4; 46.0 Number of behaviors exhibited
Phase 4 N=44 Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study
Drug Induced Hyperglycemia · Secondary Hyperlipidemia
Primary: Fasting Glucose (mg/dL) — 94 mg/dL
N/A N=57 Intervention to Reduce Stress in 0-5 Year Olds With Burns
Stress, Psychological · Post-Traumatic Stress Disorder · Major Injury
Primary: Change From Baseline in Burn Outcomes Questionnaire Short Form (0-4 Year Old Version) at Six Months — -4.9; -4.5 units on a scale
N/A N=406 Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment
Post-Traumatic Stress Disorder
Primary: Completeness and Quality of PTSD Interview — 84.8; 29.8; 76.2; 3.1 percentage of criteria PTSD assessment — p=<.001
Phase 3 N=90 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Indolent Non-Hodgkin's Lymphoma · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events — 298; 302 number of adverse events
Phase 3 N=355 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Gastric Cancer · Adenocarcinoma
Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473
Phase 3 N=480 Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo
Acne
Primary: Improvement in Acne — -74; -76; -58 Percent change
Phase 3 N=220 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Progression-Free Survival — NA; 5.5 months — p=< 0.0001
Phase 3 N=447 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Lymphoma, Large-Cell, Diffuse
Primary: Progression-free Survival as Assessed by Independent Reviewers — 2.14; 1.81 Months — p=0.333